Notice of Special Interest (NOSI): The Role of the Immune System in Aging Brain and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (NOT-AG-24-010)

Sponsor: National Institute on Aging, National Institute of Allergy and Infectious Diseases

Award: This initiative relates to the following notices of funding opportunities (NOFOs): PAR-22-093 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional); PAR-22-094 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional).

Due Date: This notice applies to due dates on or after November 12, 2024 and subsequent receipt dates through December 31, 2027.

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) (PA-25-080)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-24-293)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) (RFA-NS-25-018)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-25-051)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) (RFA-MH-26-120)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) (RFA-NS-25-017)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Administrative Supplements to Promote Diversity in Research and Development Small Businesses SBIR/STTR (Admin Supp Clinical Trial Not Allowed) (PA-24-255)

Sponsor: National Institutes of Health, Centers for Disease Control and Prevention

Award: Individual(s) must have support under an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Application budgets are limited to no more than the amount of the current parent award. The project and budget periods must be within the currently approved project period for the existing parent award.

Due Date: Applications are accepted on a rolling basis at any time starting 30 days after the Open Date (varies by IC) until the expiration date (October 14, 2027).

Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed) (RFA-AG-25-032)

Sponsor: National Institute on Aging

Award: Application budgets are limited to $400,000 in direct cost per year. The project period is limited to 5 years.

Due Date: Letter of Intent due October 7, 2024. Application due November 07, 2024 or February 14, 2025.

NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) (PAR-24-271)

Sponsor: National Institute on Aging

Due Date: Multiple due dates; see announcement.

Clinical and Translational Science Award (UM1 Clinical Trial Optional) (PAR-24-272)

Sponsor: National Center for Advancing Translational Sciences

Due Date: Multiple due dates; see announcement.

Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries for Aging and AD and ADRD Research (R03 Clinical Trial Not Allowed) (RFA-AG-25-031)

Sponsor: National Institute on Aging

Award: Application budgets are limited to $100,000 in direct cost per year. The project period is limited to 2 years.

Due Date: Letter of Intent due October 7, 2024. Application due November 07, 2024 or February 14, 2025.

Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional) (PAR-24-273)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required (RFA-FD-25-001)

Sponsor: U.S. Food and Drug Administration

Due Date: 2024 dates: LOI due September 22, 2024; application due October 22, 2024. 2025 dates: LOI due September 21, 2025; application due October 21, 2025.

McKnight Scholar Awards

Sponsor: The McKnight Endowment Fund for Neuroscience

Award: Applicants for the McKnight Scholar Awards must be independent investigators at not-for-profit research institutions in the United States and must hold a faculty position at the rank of Assistant Professor and must have served at that rank for less than five years at the application deadline. Each Scholar will receive $75,000 annually in 2025, 2026, and 2027. Funds may be used in any way that will facilitate development of the Scholar’s research program, but not for indirect costs.

Due Date: January 13, 2025 at 5 PM Central Time.